• SPX
  • $5,970.42
  • 0.37 %
  • $21.71
  • DJI
  • $44,222.21
  • 0.8 %
  • $351.85
  • N225
  • $38,283.85
  • 0.68 %
  • $257.68
  • FTSE
  • $8,262.08
  • 1.38 %
  • $112.81
  • IXIC
  • $19,012.14
  • 0.21 %
  • $39.72
Protagonist Therapeutics, Inc. (PTGX) Stock Price, News & Analysis

Protagonist Therapeutics, Inc. (PTGX) Stock Price, News & Analysis

Currency in USD Disclaimer

$45.09

$3.44

(8.26%)

Day's range
$42.44
Day's range
$47.5
50-day range
$33.31
Day's range
$48.89
  • Country: US
  • ISIN: US74366E1029
52 wk range
$16.8
Day's range
$48.89
  • CEO: Dr. Dinesh V. Patel Ph.D.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 21.81
  • Piotroski Score 6.00
  • Grade Buy
  • Symbol (PTGX)
  • Company Protagonist Therapeutics, Inc.
  • Price $45.09
  • Changes Percentage (8.26%)
  • Change $3.44
  • Day Low $42.44
  • Day High $47.50
  • Year High $48.89

Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 02/25/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $50.00
  • High Stock Price Target $50.00
  • Low Stock Price Target $50.00
  • Potential Upside/Downside N/A
  • Consensus Rating Strong Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) $2.54
  • Trailing P/E Ratio 13.7
  • Forward P/E Ratio 13.7
  • P/E Growth 13.7
  • Net Income $-78,955,000

Income Statement

Quarterly

Annual

Latest News of PTGX

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Protagonist Therapeutics, Inc. Frequently Asked Questions

  • What were the earnings of PTGX in the last quarter?

    In the last quarter Protagonist Therapeutics, Inc. earnings were on Thursday, November, 7th. The Protagonist Therapeutics, Inc. maker reported -$0.54 EPS for the quarter, beating analysts' consensus estimates of -$0.59 by $0.05.

  • What is the Protagonist Therapeutics, Inc. stock price today?

    Today's price of Protagonist Therapeutics, Inc. is $45.09 — it has increased by +8.26% in the past 24 hours. Watch Protagonist Therapeutics, Inc. stock price performance more closely on the chart.

  • Does Protagonist Therapeutics, Inc. release reports?

    Yes, you can track Protagonist Therapeutics, Inc.'s financials in yearly and quarterly reports directly on Stocks.News.

  • What is the Protagonist Therapeutics, Inc. stock forecast?

    Watch the Protagonist Therapeutics, Inc. chart and read a more detailed Protagonist Therapeutics, Inc. stock forecast to see what analysts suggest you do with its shares.

  • What is Protagonist Therapeutics, Inc. stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by Protagonist Therapeutics, Inc. stock ticker.

  • How to buy Protagonist Therapeutics, Inc. stocks?

    Like other stocks, PTGX shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is Protagonist Therapeutics, Inc.'s EBITDA?

    Protagonist Therapeutics, Inc. measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Protagonist Therapeutics, Inc.’s financial statements.

  • What is the Protagonist Therapeutics, Inc.'s net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is -1.3159166667, which equates to approximately -131.59%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in Protagonist Therapeutics, Inc. stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including Protagonist Therapeutics, Inc.'s financials relevant news, and technical analysis. Protagonist Therapeutics, Inc.'s technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for Protagonist Therapeutics, Inc. stock currently indicates a “sell” signal. For more insights, review Protagonist Therapeutics, Inc.’s technical analysis.

  • A revenue figure for Protagonist Therapeutics, Inc. for its last quarter?

    Protagonist Therapeutics, Inc. published it's last quarterly revenues at $4.68 M.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.